Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01106950|
Recruitment Status : Terminated (study drug (Ontak) no longer available)
First Posted : April 20, 2010
Results First Posted : June 26, 2013
Last Update Posted : December 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Leukemia, Myelogenous, Acute||Biological: Natural Killer Cells Drug: Fludarabine Drug: Cyclophosphamide Drug: Denileukin diftitox Procedure: Donor lymphapheresis Drug: IL-2||Phase 2|
Patients achieving a complete remission and neutrophil recovery (ANC > 500) for at least 4 weeks will be considered for allogeneic transplant to prolong remission (independent of this study).
All patients, including those who go on to transplant, will be followed to determine disease free survival, treatment related mortality, and time to relapse.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||December 2012|
Experimental: Treated Patients
Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
Biological: Natural Killer Cells
Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
Other Name: Fludara
Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
Other Name: Cytoxan
Drug: Denileukin diftitox
12 ug/kg/day will be administered on day -1 and day -2 intravenously.
Other Name: Ontak
Procedure: Donor lymphapheresis
Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
Other Name: Interleukin-2
- Percent of Patients With Successful Expansion of Natural Killer Cells After Infusion [ Time Frame: Day 14 ]The primary objective of this study was to estimate the incidence of in vivo expansion of natural killer (NK) cells 14 days after infusion of an allogeneic donor product enriched for NK progenitors. Successful in vivo donor NK cell expansion was defined by measuring an absolute circulating donor-derived NK cell count of >100 cells/ul in the patient's peripheral blood 14 days after infusion.
- Percent of Patients With Complete Remission of Disease [ Time Frame: At least 4 weeks after last dose (28 days) ]Disease response was defined as complete remission (disease response) by morphologic criteria including <5% blasts in a moderately cellular or cellular marrow. Complete remission was also correlated with NK cell expansion in vivo, IL-15 levels and donor/recipient KIR B genotyping, and Treg depletion.
- Percent of Patients With Disease Free Survival [ Time Frame: Month 6 ]Number of patients alive and disease free at 6 months. The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
- Percent of Patients With Incidence of Relapse [ Time Frame: Month 6 ]Number of patients who have had a relapse(the return of disease after its apparent recovery/cessation) after obtaining a complete remission of their disease.
- Number of Patients With Treatment-Related Death [ Time Frame: Day 100 ]Number of patients who died within the first 100 days of treatment due to toxicity.
- Percent of Patients With Natural Killer Cell Expansion Versus KIR Genotype Versus Treg Depletion [ Time Frame: Day 14 ]Association between in vivo natural killer (NK) cell expansion and complete response without platelet recovery (CRp) with donor killer immunoglobulin-like (KIR) genotype and Treg depletion. In vivo donor NK cell expansion was correlated with regulatory T-cell (Treg) depletion as detected on flow cytometry.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01106950
|United States, Minnesota|
|Masonic Cancer Center, University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Jeffrey S. Miller, M.D.||Masonic Cancer Center, University of Minnesota|